Japanese Patients diagnosed as COVID-19
Conditions
Interventions
None listed
Sponsors
The Japanese Association for Infectious Diseases
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Japanese patients who were diagnosed with COVID-19 after January 1, 2020 by any of the following methods, reported to Local Government in accordance with Infectious Disease Law in Japan, and underwent inpatient COVID-19 treatment at a medical institution: *Detection of pathogens by isolation and identification *Detection of pathogen genes by nucleic acid amplification [polymerase chain reaction (PCR), Loop-Mediated Isothermal Amplification (LAMP), etc.] from specimens *Detection of antigens of pathogens by antigen qualitative test *Detection of antigens of pathogens by antigen quantitative test (2)Japanese patients who were discharged (including death) or transferred to another hospital after completion of inpatient treatment for COVID-19 at a medical institution by March 31, 2021.
Exclusion criteria
Exclusion criteria: (1)Patients refusing to provide medical information for this research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To explore potential risk factors which are associated with severe COVID-19 in Japanese patients. Definitions of Severe COVID-19: Clinical condition which requires treatment with mechanical ventilator, extracorporeal membrane oxygenation (ECMO), newly introduced blood purification therapy [CHDF (continuous hemodiafiltration) for COVID-19 treatment], or death | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) Association between severe COVID-19 and blood type. (2) Association between Drugs for Treatment of Underlying Diseases and severe COVID-19 (3) Association between lymphocyte count / lymphocyte subsets and severe COVID-19 (4) Association between Vaccination History and severe COVID-19 (5) Association between Allergic Diseases and severe COVID-19 (6) Alternative definitions of severe COVID-19 (7) Predictive factors of complications associated with COVID-19, such as thrombosis (deep venous thrombosis, pulmonary embolism, cerebral infarction, myocardial infarction, and other thromboembolism) (8) Association between prognosis of COVID-19 and anticoagulant use (9) Frequency and Clinical Characteristics of Infectious (Bacterial, Fungal, and Viral) Complications during COVID-19 treatment. (10) Clinical characteristics (disease duration, duration suffering from fever, etc.) of the elderly patients with COVID-19 (11) Causative microorganisms and Clinical Characteristics of Infectious Complications associated with COVID-19 (12) Types, incidence and prognosis of sequelae associated with COVID-19 (13) Clinical Characteristics of patients with COVID-19 who require Obstetric Treatment (14) Clinical Characteristics of patients with COVID-19 who require Surgical Treatment (15) Initial symptoms of COVID-19 | — |
Countries
Japan
Contacts
Public ContactKazuyoshi Kawakami
Tohoku University Medical Microbiology, Mycology and Immunology, Graduate School of Medicine
Outcome results
None listed